VIDEO: Unmet needs in mantle cell lymphoma

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes.

Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

The major unmet need is what to do with patients who've, you know, been through all of the standard approaches including BTK inhibitors and CAR T-cell therapy. In addition, many patients are really not suitable for CAR T-cell therapy for a variety of reasons. Maybe because of their age, performance status, comorbidities, geographic or so social restrictions on their ability to get to a a center that has CAR T-cell therapy. So in the community, these patients need better therapies that can be delivered closer to home. And in that sense, I think the bispecific class, agents of the bispecifics, are very encouraging.